CA2065553C - Preparations de facteur viii stabilise - Google Patents

Preparations de facteur viii stabilise Download PDF

Info

Publication number
CA2065553C
CA2065553C CA002065553A CA2065553A CA2065553C CA 2065553 C CA2065553 C CA 2065553C CA 002065553 A CA002065553 A CA 002065553A CA 2065553 A CA2065553 A CA 2065553A CA 2065553 C CA2065553 C CA 2065553C
Authority
CA
Canada
Prior art keywords
solution
viii
activity
factor viii
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002065553A
Other languages
English (en)
Other versions
CA2065553A1 (fr
Inventor
Wilfried Freudenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Behring GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6429102&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2065553(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Behring GmbH filed Critical Aventis Behring GmbH
Publication of CA2065553A1 publication Critical patent/CA2065553A1/fr
Application granted granted Critical
Publication of CA2065553C publication Critical patent/CA2065553C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002065553A 1991-04-09 1992-04-08 Preparations de facteur viii stabilise Expired - Lifetime CA2065553C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4111393.4 1991-04-09
DE4111393A DE4111393A1 (de) 1991-04-09 1991-04-09 Stabilisierte faktor viii-praeparationen

Publications (2)

Publication Number Publication Date
CA2065553A1 CA2065553A1 (fr) 1992-10-10
CA2065553C true CA2065553C (fr) 2003-06-10

Family

ID=6429102

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002065553A Expired - Lifetime CA2065553C (fr) 1991-04-09 1992-04-08 Preparations de facteur viii stabilise

Country Status (12)

Country Link
US (1) US5565427C1 (fr)
EP (1) EP0508194B1 (fr)
JP (2) JP3777467B2 (fr)
KR (1) KR100231398B1 (fr)
AT (1) ATE160942T1 (fr)
AU (1) AU651188B2 (fr)
CA (1) CA2065553C (fr)
DE (2) DE4111393A1 (fr)
DK (1) DK0508194T3 (fr)
ES (1) ES2111579T4 (fr)
GR (1) GR3025873T3 (fr)
IE (1) IE921124A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058226B2 (en) 1999-02-22 2011-11-15 Baxter International Inc. Albumin-free factor VIII formulations
AU2009289212B2 (en) * 2008-09-03 2015-02-12 Octapharma Ag New protecting compositions for recombinantly produced factor VIII
US10512674B2 (en) 2008-11-07 2019-12-24 Baxalta Incorporated Factor VIII formulations

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE316981T1 (de) * 1992-10-02 2006-02-15 Inst Genetics Llc Zusammensetzung, welche den koagulationsfaktor viii beinhalted; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) † 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2386228A1 (fr) * 1999-10-04 2001-04-12 Chiron Corporation Compositions pharmaceutiques liquides stabilisees contenant des polypeptides inhibiteurs de la voie du facteur tissulaire (tfpi)
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
ATE424215T1 (de) 2003-01-08 2009-03-15 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
CN102139114A (zh) 2003-02-26 2011-08-03 尼克塔治疗公司 聚合物-因子viii部分缀合物
DE10333317A1 (de) † 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
EP1750733B1 (fr) * 2004-05-03 2013-12-11 Emory University Methode d'administration de facteur viii sans domaine b porcin
US7884075B2 (en) 2004-12-27 2011-02-08 Baxter International Inc. Polymer-factor VIII-von Willebrand factor-conjugates
CA2614006C (fr) * 2005-07-02 2014-11-04 Arecor Limited Systemes aqueux stables comprenant des proteines
WO2007126808A1 (fr) * 2006-03-31 2007-11-08 Baxter International Inc Facteur viii pégylé
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
AU2007347505B2 (en) * 2007-02-23 2012-11-22 Sk Bioscience Co., Ltd. Process for producing and purifying factor VIII and its derivatives
AU2008245821B2 (en) * 2007-04-26 2013-07-04 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
EP2331569A1 (fr) 2008-08-21 2011-06-15 Octapharma AG Facteurs humains viii et ix produits par recombinaison génétique
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
LT2440239T (lt) * 2009-06-09 2017-12-11 Prolong Pharmaceuticals, LLC Hemoglobino kompozicijos
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
CA2810734A1 (fr) * 2010-09-17 2012-03-22 Baxter International Inc. Stabilisation des immunoglobulines par une formulation aqueuse additionnee d'histidine a un ph faiblement acide a neutre
DK2635297T3 (da) 2010-11-05 2019-05-06 Baxalta GmbH En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet
WO2012138416A1 (fr) 2011-04-08 2012-10-11 Bio-Rad Laboratories, Inc. Mélanges de réaction pcr à activité non spécifique réduite
CN103562410B (zh) 2011-04-08 2016-09-28 伯乐实验室公司 具有降低的非特异性活性的sso7-聚合酶缀合物
US9394353B2 (en) 2011-10-18 2016-07-19 Csl Limited Method for improving the stability of purified factor VIII after reconstitution
CN102580062B (zh) * 2012-03-09 2017-03-08 中国医学科学院输血研究所 人凝血因子VIII与vWF复合物或人凝血因子VIII制剂的干热处理稳定剂
JP2014138614A (ja) * 2014-04-09 2014-07-31 Sk Chemicals Co Ltd 第ｖｉｉｉ因子とその誘導体の製造及び精製方法
JP6516829B2 (ja) 2014-08-04 2019-05-22 シーエスエル、リミテッド 第ｖｉｉｉ因子製剤
WO2021001522A1 (fr) 2019-07-04 2021-01-07 CSL Behring Lengnau AG Facteur de von willebrand (vwf) tronqué pour augmenter la stabilité in vitro du facteur viii de coagulation
WO2022099223A2 (fr) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Limited Purification de fviii à partir du plasma au moyen d'une adsorption d'oxyde de silicium

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB941019A (en) * 1961-04-27 1963-11-06 Crookes Lab Ltd Improvements in and relating to the stability of anti-haemophilic globulin (factor viii)
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
US4650858A (en) * 1983-03-21 1987-03-17 Nordisk Gentofte A/S Concentrate of the antihemophilic factor VIII and a process for producing it
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
CA1329760C (fr) * 1987-10-29 1994-05-24 Ted C. K. Lee Formulation de plasma et de proteines recombinantes dans des milieux a grande force ionique
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
FR2644064B1 (fr) * 1989-02-17 1994-05-27 Aquitaine Dev Transf Sanguine Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
DE3926034C3 (de) * 1989-08-07 1996-11-21 Behringwerke Ag Verfahren zur Herstellung eines stabilen Faktors VIII
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
IT1248723B (it) * 1990-06-12 1995-01-26 Scalvo S P A Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo
JP4021982B2 (ja) * 1998-03-03 2007-12-12 信越化学工業株式会社 ハイブリッド型ウイグラ

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058226B2 (en) 1999-02-22 2011-11-15 Baxter International Inc. Albumin-free factor VIII formulations
US8372800B2 (en) 1999-02-22 2013-02-12 Baxter International Inc. Albumin-free factor VIII formulations
US8765665B2 (en) 1999-02-22 2014-07-01 Baxter International Inc. Albumin-free factor VIII formulations
US9352027B2 (en) 1999-02-22 2016-05-31 Baxalta Incorporated Albumin-free factor VIII formulations
US9669076B2 (en) 1999-02-22 2017-06-06 Baxalta Incorporated Albumin-free factor VIII formulations
AU2009289212B2 (en) * 2008-09-03 2015-02-12 Octapharma Ag New protecting compositions for recombinantly produced factor VIII
US10512674B2 (en) 2008-11-07 2019-12-24 Baxalta Incorporated Factor VIII formulations
US11020459B2 (en) 2008-11-07 2021-06-01 Baxalta Incorporated Factor VIII formulations

Also Published As

Publication number Publication date
AU1470292A (en) 1992-10-15
AU651188B2 (en) 1994-07-14
JP3777467B2 (ja) 2006-05-24
ES2111579T4 (es) 2011-12-29
CA2065553A1 (fr) 1992-10-10
GR3025873T3 (en) 1998-04-30
US5565427A (en) 1996-10-15
KR100231398B1 (ko) 1999-11-15
IE921124A1 (en) 1992-10-21
JP2002097199A (ja) 2002-04-02
ATE160942T1 (de) 1997-12-15
JPH0597702A (ja) 1993-04-20
US5565427C1 (en) 2002-07-23
ES2111579T3 (es) 1998-03-16
EP0508194B1 (fr) 1997-12-10
JP3809501B2 (ja) 2006-08-16
DE4111393A1 (de) 1992-10-15
DE59209051D1 (de) 1998-01-22
KR920019371A (ko) 1992-11-19
EP0508194A1 (fr) 1992-10-14
DK0508194T3 (da) 1998-08-24

Similar Documents

Publication Publication Date Title
CA2065553C (fr) Preparations de facteur viii stabilise
CA1329760C (fr) Formulation de plasma et de proteines recombinantes dans des milieux a grande force ionique
CA1329542C (fr) Formulation de plasma et de proteines recombinantes dans des milieux a faible force ionique
US5605884A (en) Factor VIII formulations in high ionic strength media
EP0638091B1 (fr) Solubilisation et stabilisation ameliorees du complexe du facteur viii
JP3827713B2 (ja) 凝固因子ｖｉｉｉからなる医薬製剤
US6103693A (en) Method for isolation of highly pure von willebrand factor
JP3939750B2 (ja) 凝固第ｖｉｉｉ因子の皮下、筋肉内または皮内投与用の製薬調合剤
JP4879104B2 (ja) 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方
US5733873A (en) Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer
US5691312A (en) Pharmaceutical for subcutaneous or intramuscular administration containing polypeptides
CA2216098C (fr) Formulation de protein comprenant le facteur de coagulation viii ou ix dans une solution aqueuse
SK283002B6 (sk) Prípravok s obsahom koagulačného faktora VIII
EP0410207B1 (fr) Stabilisation de protéines hautement purifiées
JPH0788309B2 (ja) 抗血友病因子濃縮物
MXPA03008545A (es) Composiciones farmaceuticas que contienen la hormona humana del crecimiento.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry